Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield
As of December 11, 2025, Pfizer Inc. (NYSE: PFE) is trying to rewrite its post‑COVID story. The stock trades around $25.66 per share, after a choppy year of guidance upgrades, obesity-drug M&A, aggressive cost cuts and fresh regulatory wins in oncology and rare disease. Since November 21, 2025, a cluster of headlines — from an FDA approval in bladder cancer to a new GLP‑1 weight‑loss deal and expanding cost‑saving measures — has shifted how analysts and investors think about Pfizer’s earnings power going into 2026 and beyond. Pfizer stock today: price, yield and recent performance Pfizer’s board declared a $0.43